A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.

Drug-Induced Liver Injury — Types and Phenotypes

(2019) Jay H. Hoofnagle et al.   NEW ENGLAND JOURNAL OF MEDICINE

FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver

(2018) Romeo Papazyan et al.   JOURNAL OF LIPID RESEARCH

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

(2018) Christophe Corpechot et al.   NEW ENGLAND JOURNAL OF MEDICINE

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

(2017) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge

(2016) Serge J. Zweers et al.   Hepatology International

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

(2015) Willem J. Lammers et al.   GASTROENTEROLOGY

Fibrates and cholestasis

(2015) Nisanne S. Ghonem et al.   HEPATOLOGY

The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis

(2015) Marco Carbone et al.   HEPATOLOGY

Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

(2014) Willem J. Lammers et al.   GASTROENTEROLOGY

The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

(2014) Michal Pawlak et al.   HEPATOLOGY

Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development

(2014) Iker Uriarte et al.   INTERNATIONAL JOURNAL OF CANCER

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2013) Bart Staels et al.   HEPATOLOGY

Cystatin C versus Creatinine in Determining Risk Based on Kidney Function

(2013) Michael G. Shlipak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience

(2012) D. E. Bonds et al.   DIABETOLOGIA

Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid

(2012) Marco Carbone et al.   GASTROENTEROLOGY

Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis

(2012) Fei Li et al.   JOURNAL OF LIPID RESEARCH

Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle

(2011) Giulia Maria Camerino et al.   BIOCHEMICAL PHARMACOLOGY

Primary biliary cirrhosis

(2011) Carlo Selmi et al.   LANCET

The 5-D itch scale: a new measure of pruritus

(2009) S. Elman et al.   BRITISH JOURNAL OF DERMATOLOGY

Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid

(2009) Edith M.M. Kuiper et al.   GASTROENTEROLOGY

Primary biliary cirrhosis

(2009) Keith D. Lindor et al.   HEPATOLOGY